Navigating Drug-Drug Interactions in Clinical Drug Development: A Tutorial.

Area of Science:

• Pharmacology
• Drug Development
• Clinical Research

Background:

• Drug-drug interactions (DDIs) can significantly impact a drug's safety and efficacy.
• Understanding DDIs is crucial for managing clinical trial inclusion/exclusion criteria and drug labeling.

Purpose of the Study:

• To provide guidelines and regulatory insights for evaluating DDIs in drug development.
• To equip researchers with methodologies for identifying and assessing victim and perpetrator DDIs.
• To serve as a comprehensive resource for DDI considerations during new molecular entity development.

Main Methods:

• Exploration of the mechanistic basis of DDIs affecting absorption, distribution, metabolism, and excretion (ADME).
• Utilization of in vitro studies for early screening of enzyme- and transporter-mediated interactions.
• Application of in vivo studies to confirm in vitro findings.
• Integration of computational modeling, including physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (popPK) approaches.

Main Results:

• Early identification of potential perpetrator drugs through in vitro screening.
• Confirmation of interactions using in vivo studies.
• Prediction of victim and perpetrator interactions via computational modeling prior to or alongside clinical trials.

Conclusions:

• A systematic approach combining in vitro, in vivo, and computational methods is essential for comprehensive DDI evaluation.
• Effective DDI assessment supports informed decision-making in drug development, ensuring patient safety.
• This tutorial offers a valuable framework for researchers navigating DDI complexities in new drug development.